For UK HealthTech companies
NHS decision-makers are landing on your website and leaving without a word
Trust CIOs and ICB commissioners need specific clinical evidence, procurement language, and relevant calls to action, not a contact form built for patients. Most healthtech sites quietly lose the conversations that become contracts.
Two minutes. Solva follows up with specific NHS conversion and messaging options.
- High website traffic but low enquiry form submissions or demo requests
- Sales teams spending excessive time qualifying leads that are not a good fit
- Marketing budget being spent on driving traffic that doesn't translate into measurable sales pipeline
- Lack of clear pathways for NHS decision-makers to access relevant information and engage
- Inefficient allocation of marketing resources on activities that don't yield qualified leads
- Increased workload for sales teams due to a higher volume of unqualified leads or manual lead nurturing
- Lost revenue opportunities from potential NHS contracts
- Increased cost per acquisition (CPA) for qualified leads
- Perception as a generic or non-specialist provider within the NHS ecosystem
- Difficulty in building trust and credibility with key NHS stakeholders
The average conversion rate for B2B websites in the Health & Social Care sector in the UK is 2.3% (Ruler Analytics, 2026)
Source: https://www.ruleranalytics.com/blog/insight/conversion-rate-by-industry/
Frequently asked questions
Why does this problem persist?
Most healthtech websites are built for investors or patients, not for NHS procurement leads. They lack the specific language, evidence, and calls to action that a trust CIO or ICB commissioner needs to take the next step. Generic 'contact us' forms have near-zero conversion in B2B healthcare.
What is the cost of leaving it unaddressed?
The true cost of an in-house Sales Development Representative (SDR) in the UK, responsible for lead generation, is £60,000–£67,000 per year (Flowd, 2026)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.